Drugmakers, including GSK, have ben working hard to develop new treatments for HIV that involve fewer drugs being taken less frequently.
FTSE 100-listed Glaxo already knew that its combination of cabotegravir and rilpivirine could be taken once a month and keep the virus suppressed.
But a phase III trial, called ATLAS-2M, has shown that the bi-monthly injection is just as effective as the once-monthly jab.
“We are excited to report that for the first time since the AIDS epidemic started more than 30 years ago, our ATLAS-2M study has demonstrated that it is possible to maintain suppression of the HIV virus with an injectable regimen containing two drugs administered every two months,” said Kimberley Smith, head of R&D at Glaxo’s majority-owned HIV division, ViiV Healthcare.
“This is further progress in our efforts to reduce the number of medicines a person living with HIV must take while also reducing the frequency of treatments.
“The ATLAS-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year. Approval of this regimen would mark a significant change in the HIV treatment paradigm.”